Shares of Haemonetics Co. (NYSE:HAE) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $117.75.

A number of research analysts recently issued reports on HAE shares. Barrington Research reiterated an “outperform” rating and set a $116.00 price objective (up from $112.00) on shares of Haemonetics in a research note on Wednesday, May 8th. Zacks Investment Research cut Haemonetics from a “hold” rating to a “sell” rating in a report on Tuesday, April 2nd. Raymond James raised Haemonetics from a “market perform” rating to an “outperform” rating and set a $110.00 price target on the stock in a report on Tuesday, May 14th. Finally, TheStreet raised Haemonetics from a “c+” rating to a “b-” rating in a report on Tuesday, May 7th.

Shares of NYSE:HAE opened at $111.83 on Tuesday. The company has a market cap of $5.64 billion, a P/E ratio of 46.79, a P/E/G ratio of 2.78 and a beta of 0.67. The company has a quick ratio of 1.62, a current ratio of 2.44 and a debt-to-equity ratio of 0.48. Haemonetics has a 12-month low of $80.24 and a 12-month high of $117.56.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.55 by $0.06. The company had revenue of $249.30 million during the quarter, compared to the consensus estimate of $250.62 million. Haemonetics had a return on equity of 18.88% and a net margin of 5.69%. The firm’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 EPS. On average, sell-side analysts expect that Haemonetics will post 2.93 earnings per share for the current year.

In related news, EVP Michelle L. Basil sold 7,187 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $103.49, for a total value of $743,782.63. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Simon sold 1,248 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $109.37, for a total value of $136,493.76. The disclosure for this sale can be found here. Over the last three months, insiders sold 100,306 shares of company stock worth $9,720,660. 1.04% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cardinal Capital Management lifted its holdings in Haemonetics by 2.0% in the 1st quarter. Cardinal Capital Management now owns 8,260 shares of the medical instruments supplier’s stock worth $722,000 after purchasing an additional 160 shares in the last quarter. Tyers Asset Management LLC raised its holdings in shares of Haemonetics by 3.6% during the 1st quarter. Tyers Asset Management LLC now owns 5,568 shares of the medical instruments supplier’s stock worth $487,000 after acquiring an additional 192 shares in the last quarter. One Wealth Advisors LLC raised its holdings in shares of Haemonetics by 5.2% during the 1st quarter. One Wealth Advisors LLC now owns 4,494 shares of the medical instruments supplier’s stock worth $393,000 after acquiring an additional 221 shares in the last quarter. Tocqueville Asset Management L.P. raised its holdings in shares of Haemonetics by 5.4% during the 4th quarter. Tocqueville Asset Management L.P. now owns 4,821 shares of the medical instruments supplier’s stock worth $482,000 after acquiring an additional 247 shares in the last quarter. Finally, Riverhead Capital Management LLC raised its holdings in shares of Haemonetics by 5.0% during the 1st quarter. Riverhead Capital Management LLC now owns 6,271 shares of the medical instruments supplier’s stock worth $549,000 after acquiring an additional 300 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Further Reading: The primary rules of Elliott Wave theory

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.